Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR5 | Q9H228 | 15/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 11/20 | 0.40 |
| ▸ | PRKX | P51817 | 1/20 | 0.40 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.40 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.39 |
| ▸ | LTK | P29376 | 1/20 | 0.38 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2571918 | 1.00 | S1PR5 (0.41) | S1PR5S1PR1PRKXACVR1PDCD1 | |
| SCHEMBL2568870 | 0.83 | DDR1 (0.35) | S1PR5S1PR1PDCD1CD274 | |
| SCHEMBL2568868 | 0.83 | DDR1 (0.35) | S1PR5S1PR1PDCD1CD274 | |
| SCHEMBL2569481 | 0.83 | DDR1 (0.35) | S1PR5S1PR1PDCD1CD274 | |
| SCHEMBL406722 | 0.79 | S1PR5 (0.59) | S1PR5S1PR1 | |
| SCHEMBL406723 | 0.79 | S1PR5 (0.59) | S1PR5S1PR1 | |
| SCHEMBL24075435 | 0.72 | S1PR5 (0.52) | S1PR5S1PR1PRKXACVR1PDCD1 | |
| SCHEMBL24075687 | 0.72 | S1PR5 (0.52) | S1PR5S1PR1PRKXACVR1PDCD1 | |
| SCHEMBL25254921 | 0.72 | S1PR5 (0.52) | S1PR5S1PR1PRKXACVR1PDCD1 | |
| SCHEMBL16591188 | 0.71 | KDM1A (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354398-B2 | Substituted isoxazole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-15 | — | — | US | disclosed |
| US-20110300165-A1 | SUBSTITUTED ISOXAZOLE COMPOUNDS | The Board of TRustees of the University of Illinoi University of Illinios (US) | 2011-12-08 | — | — | US | disclosed |
| EP-2382212-A1 | SUBSTITUTED OXADIAZOLE DERIVATIVES AS S1P AGONISTS IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | Bristol-Myers Squibb Company (US) | 2011-11-02 | — | — | EP | disclosed |
| WO-2010085581-A1 | SUBSTITUTED OXADIAZOLE DERIVATIVES AS S1P AGONISTS IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110300165-A1 | SUBSTITUTED ISOXAZOLE COMPOUNDS | S1PR4, S1PR3, S1PR1 | S1PR5 4/4885S1PR1 3/4885PRKX 573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.